Carotid intima-media thickness in mainly non-obese women with polycystic ovary syndrome and age-matched controls

• Published in: Obstetrics & gynecology science 2013, 56(04), 610, pp.249-255
• Main Authors: Kim, Jin Ju, Choi, Young Min, Kang, Jin Hwa, Hwang, Kyu Ri, Chae, Soo Jin, Kim, Sun Mie, Ku, Seung Yup, Kim, Seok Hyun, Kim, Jung Gu, Moon, Shin Yong
• Format: Article
• Language: English
• Subjects: Original; 산부인과학
• ISSN: 2287-8572; 2287-8580
• DOI: 10.5468/ogs.2013.56.4.249

Metabolic disturbances are well-recognized clinical features of polycystic ovary syndrome (PCOS). Carotid intima-media thickness (CIMT) has been widely used as a surrogate marker of atherosclerosis and cardiovascular disease (CVD). CIMT in women with PCOS has been investigated in many studies, but there has been only one report in the Korean population. The aim of the present study was to compare the presence of subclinical atherosclerosis in young untreated Korean women with PCOS and age-matched controls, specifically by measuring their CIMT. CIMT was measured by one radiologist in 56 PCOS patients and 56 controls. To compare the CIMT according to PCOS phenotypes, women with PCOS were divided into two subgroups according to the presence of hyperandrogenism. Although PCOS patients were more obese and had higher blood pressure and insulin resistance index than the age-matched controls, the CIMT was not different between the two groups (0.49 ± 0.09 mm in PCOS patients vs. 0.50 ± 0.11 mm in controls, respectively, p = 0.562). When the CIMT in the control group was compared with hyperandrogenic and non-hyperandrogenic PCOS groups, also no significant differences were found. Despite the significant differences in some vascular risk factors between women with PCOS and controls, PCOS patients did not have a significantly higher CIMT (even in the hyperandrogenic subgroups). Although our study did not show the increased risk of subclinical atherosclerosis in PCOS patients, the role of CIMT continues to be investigated considering the importance of screening and monitoring CVD risk factors in women with PCOS.